RxDoctor Payments Data

Andrew Corsello, MD

Clinical Cardiac Electrophysiology · Scarborough, MENPI 1265412951

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,144 of the $1,603 with a category attached, or 71.4%. Abbott accounts for 69.2% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $748, 4.4 times the $171 reported in 2019.

$1,603in general payments, 2019–2025

Across 19 payments — averaging $84.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Medtronic$260
  • Atricure, Inc.$171
  • Biosense Webster, Inc.$62
$45,106in research payments, 2019–2025

Across 24 payments — averaging $1879.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$45K

What the payments were for

  • Travel & lodging$45929%
  • Food & beverage$1,14471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott11$1,110
Medtronic5$260
Atricure, Inc.2$171
Biosense Webster, Inc.1$62

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$117,388
Medicare patients
870
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$231,701
XareltoRivaroxaban57$76,741
Droxidopa12$10,182
Dofetilide21$8,853
Metoprolol Succinate288$4,467
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,512
Verapamil SrVerapamil Hcl19$2,052
Verapamil ErVerapamil Hcl25$1,183
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$1,100
Amiodarone Hcl52$880
Flecainide Acetate23$742
Dilt-XrDiltiazem Hcl26$726
Atorvastatin Calcium45$492
Metoprolol Tartrate81$457
Carvedilol53$398

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Scarborough

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →